192 related articles for article (PubMed ID: 8586466)
1. The p53 gene and its role in human brain tumors.
Bögler O; Huang HJ; Kleihues P; Cavenee WK
Glia; 1995 Nov; 15(3):308-27. PubMed ID: 8586466
[TBL] [Abstract][Full Text] [Related]
2. Absence of p53 autoantibodies in sera from glioma patients.
Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
[TBL] [Abstract][Full Text] [Related]
3. p53 mutation, EGFR gene amplification and loss of heterozygosity on chromosome 10, 17 p in human gliomas.
Jin W; Xu X; Yang T; Hua Z
Chin Med J (Engl); 2000 Jul; 113(7):662-6. PubMed ID: 11776043
[TBL] [Abstract][Full Text] [Related]
4. Comparative assessment of the functional p53 status in glioma cells.
Kim EL; Yoshizato K; Kluwe L; Meissner H; Warnecke G; Zapf S; Westphal M; Deppert W; Giese A
Anticancer Res; 2005; 25(1A):213-24. PubMed ID: 15816541
[TBL] [Abstract][Full Text] [Related]
5. Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome.
Srivastava S; Tong YA; Devadas K; Zou ZQ; Sykes VW; Chen Y; Blattner WA; Pirollo K; Chang EH
Oncogene; 1992 May; 7(5):987-91. PubMed ID: 1373881
[TBL] [Abstract][Full Text] [Related]
6. Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant.
Klein MA; Rüedi D; Nozaki M; Dell EW; Diserens AC; Seelentag W; Janzer RC; Aguzzi A; Hegi ME
Oncogene; 2000 Nov; 19(47):5329-37. PubMed ID: 11103934
[TBL] [Abstract][Full Text] [Related]
7. p53 transdominance but no gain of function in mouse brain tumor model.
Hegi ME; Klein MA; Rüedi D; Chène P; Hamou MF; Aguzzi A
Cancer Res; 2000 Jun; 60(11):3019-24. PubMed ID: 10850451
[TBL] [Abstract][Full Text] [Related]
8. Analysis of p53 gene mutations in human glioma cell lines.
Koga H; Zhang S; Washiyama K; Ichikawa T; Onda K; Kumanishi T
Noshuyo Byori; 1996 Apr; 13(1):1-10. PubMed ID: 8916120
[TBL] [Abstract][Full Text] [Related]
9. Gain-of-function mutations in the tumor suppressor gene p53.
van Oijen MG; Slootweg PJ
Clin Cancer Res; 2000 Jun; 6(6):2138-45. PubMed ID: 10873062
[TBL] [Abstract][Full Text] [Related]
10. Germ-line exclusion of a single p53 allele by premature termination of translation in a Li-Fraumeni syndrome family.
Stolzenberg MC; Brugières L; Gardes M; Dessarps-Freichey F; Chompret A; Bressac B; Lenoir G; Bonaïti-Pellié C; Lemerle J; Feunteun J
Oncogene; 1994 Oct; 9(10):2799-804. PubMed ID: 8084585
[TBL] [Abstract][Full Text] [Related]
11. Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 4: p53 signaling pathway.
Newton HB
Expert Rev Anticancer Ther; 2005 Feb; 5(1):177-91. PubMed ID: 15757449
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage.
Kawamata H; Omotehara F; Nakashiro K; Uchida D; Shinagawa Y; Tachibana M; Imai Y; Fujimori T
Int J Oncol; 2007 May; 30(5):1089-97. PubMed ID: 17390010
[TBL] [Abstract][Full Text] [Related]
13. Anti-P53 antibodies in Brazilian brain tumor patients.
Fonseca RF; Kawamura MT; Oliveira JA; Teixeira A; Alves G; Carvalho Mda G
Genet Mol Res; 2003 Jun; 2(2):185-90. PubMed ID: 14966683
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of a novel germ line p53 mutation in familial gastric cancer in the Japanese population.
Yamada H; Shinmura K; Okudela K; Goto M; Suzuki M; Kuriki K; Tsuneyoshi T; Sugimura H
Carcinogenesis; 2007 Sep; 28(9):2013-8. PubMed ID: 17690113
[TBL] [Abstract][Full Text] [Related]
15. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
[TBL] [Abstract][Full Text] [Related]
16. Molecular alterations and lung tumors in p53 mutant mice exposed to cigarette smoke.
De Flora S; Balansky RM; D'Agostini F; Izzotti A; Camoirano A; Bennicelli C; Zhang Z; Wang Y; Lubet RA; You M
Cancer Res; 2003 Feb; 63(4):793-800. PubMed ID: 12591728
[TBL] [Abstract][Full Text] [Related]
17. PTEN gene mutations are seen in high-grade but not in low-grade gliomas.
Rasheed BK; Stenzel TT; McLendon RE; Parsons R; Friedman AH; Friedman HS; Bigner DD; Bigner SH
Cancer Res; 1997 Oct; 57(19):4187-90. PubMed ID: 9331072
[TBL] [Abstract][Full Text] [Related]
18. Mutation analysis of DKK1 and in vivo evidence of predominant p53-independent DKK1 function in gliomas.
Mueller W; Lass U; Wellmann S; Kunitz F; von Deimling A
Acta Neuropathol; 2005 Mar; 109(3):314-20. PubMed ID: 15668788
[TBL] [Abstract][Full Text] [Related]
19. Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand.
Naumann U; Kügler S; Wolburg H; Wick W; Rascher G; Schulz JB; Conseiller E; Bähr M; Weller M
Cancer Res; 2001 Aug; 61(15):5833-42. PubMed ID: 11479223
[TBL] [Abstract][Full Text] [Related]
20. Several mutant p53 proteins detected in cancer-prone families with Li-Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53.
Srivastava S; Wang S; Tong YA; Pirollo K; Chang EH
Oncogene; 1993 Sep; 8(9):2449-56. PubMed ID: 8361758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
